Guggenheim raised the firm’s price target on Merck (MRK) to $122 from $104 and keeps a Buy rating on the shares. The firm’s target raise is largely driven by inclusion of probability-adjusted revenues for Winrevair in the population investigated in the Phase 2 CADENCE trial, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck & Co. Closes $7 Billion Notes Offering
- Halozyme wins preliminary injunction against Merck’s Keytruda SC in Germany
- Merck Animal Health announces conditional FDA approval of Exzolt Cattle-CA1
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports